Key result
Verapamil infusion significantly attenuated tachycardia-induced atrial effective refractory period shortening (-4.6% vs -15.1%, P<0.001), whereas other antiarrhythmic drugs did not.
Why the study?
Does administration of antiarrhythmic drugs attenuate atrial ERP shortening induced by tachycardia in adult patients without structural heart disease?
Population
70 adult patients without structural heart disease
Comparison
Antiarrhythmic drugs administered after an… vs Baseline atrial ERP before drug infusion and…
Design
RCT, randomized to receive one of six antiarrhythmic drugs
Authors
Loading...
Verapamil may be prioritized to limit tachycardia-mediated atrial vulnerability; challenges uniform antiarrhythmic effects on electrical remodeling.
RCT (n=70)
randomized
Does administration of antiarrhythmic drugs attenuate atrial ERP shortening induced by tachycardia in adult patients without structural heart disease?
Absolute Event Rate: -4.6% vs -15.1%
p-value: p=<0.001
Verapamil, unlike other antiarrhythmic drugs, attenuates tachycardia-induced atrial refractory period shortening, though all tested drugs reduce secondary AF.
Yu et al. (1998) conducted an RCT in Atrial fibrillation (n=70). Antiarrhythmic drugs (procainamide, propafenone, propranolol, dl-sotalol, amiodarone, and verapamil) vs. Baseline/other antiarrhythmic drugs was evaluated on Atrial effective refractory period (ERP) shortening (p=<0.001). Verapamil infusion significantly attenuated tachycardia-induced atrial effective refractory period shortening (-4.6% vs -15.1%, P<0.001), whereas other antiarrhythmic drugs did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: